SCHEMBL14330663

SCHEMBL14330663

Cc1ccc2nc(C(F)(F)C(=O)c3ccc(F)cc3F)cnc2c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CES2 O00748 1/20 0.40
▸ CES1 P23141 1/20 0.40
▸ CYP3A4 P08684 1/20 0.38
▸ CYP2C9 P11712 1/20 0.38
▸ CYP2C19 P33261 1/20 0.38
▸ CTNNB1 P35222 1/20 0.38
▸ TCF7L2 Q9NQB0 1/20 0.38
▸ DHODH Q02127 1/20 0.35
▸ TP53 P04637 1/20 0.35
▸ GAA P10253 2/20 0.35
▸ MAPT P10636 2/20 0.35
▸ L3MBTL1 Q9Y468 2/20 0.35
▸ KDM4E B2RXH2 1/20 0.35
▸ ATM Q13315 1/20 0.35
▸ NPSR1 Q6W5P4 1/20 0.35
▸ GRM5 P41594 1/20 0.34
▸ CTSD P07339 1/20 0.34
▸ GUSB P08236 1/20 0.34
▸ HDAC4 P56524 1/20 0.34
▸ LMNA P02545 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14330659 0.86 CES2 (0.40) CES2CES1CYP3A4CYP2C9CYP2C19
SCHEMBL14331598 0.83 CES2 (0.38) CES2CES1CYP3A4CYP2C9CYP2C19
SCHEMBL17120565 0.80 CES2 (0.42) CES2CES1CYP2C19DHODHTP53
SCHEMBL11913027 0.77 CES2 (0.40) CES2CES1CYP3A4CYP2C9CYP2C19
SCHEMBL18650595 0.73 MAP4K4 (0.38) DHODH
SCHEMBL14330665 0.73 ACSS2 (0.40) CYP2C9GAAMAPTL3MBTL1KDM4E
SCHEMBL18654129 0.73 CES2 (0.49) CES2CES1GAALMNA
SCHEMBL14330655 0.73 CES2 (0.42) CES2CES1CYP3A4CYP2C9CYP2C19
SCHEMBL13347723 0.72 NQO2 (0.46) MAPTL3MBTL1KDM4EHDAC4LMNA
SCHEMBL14330637 0.71 CES2 (0.39) CES2CES1CYP3A4CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8940735-B2 Metalloenzyme inhibitor compounds VIAMET PHARMACEUTICALS, INC. (US) 2015-01-27 — — US disclosed
US-8883797-B2 Metalloenzyme inhibitor compounds VIAMET PHARMACEUTICALS, INC. (US) 2014-11-11 — — US disclosed
US-20130012503-A1 METALLOENZYME INHIBITOR COMPOUNDS VIAMET PHARMACEUTICALS, INC. (US) 2013-01-10 — — US disclosed
US-20120329802-A1 METALLOENZYME INHIBITOR COMPOUNDS VIAMET PHARMACEUTICALS, INC. (US) 2012-12-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130012503-A1 METALLOENZYME INHIBITOR COMPOUNDS MMEL1, GPX1, MPO CES2 286/4885CES1 198/4885CYP3A4 558/4885
US-20120329802-A1 METALLOENZYME INHIBITOR COMPOUNDS MMEL1, GPX1, MPO CES2 286/4885CES1 198/4885CYP3A4 558/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback